Standard BioTools Inc LAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.88
- Day Range
- $0.86–0.92
- 52-Week Range
- $0.80–1.72
- Bid/Ask
- $0.88 / $0.88
- Shares Outstanding
- 391.46M
- Market Cap
- $346.99M
- Volume/Avg
- 798,448 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.96
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 389
- Website
- https://www.standardbio.com
Valuation
|
Metric
|
LAB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.62 |
Price/Sales | 3.96 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LAB
|
|---|---|
Quick Ratio | 11.77 |
Current Ratio | 12.36 |
Interest Coverage | — |
Quick Ratio
LAB
Profitability
|
Metric
|
LAB
|
|---|---|
Return on Assets (Normalized) | −2.29% |
Return on Equity (Normalized) | −2.91% |
Return on Invested Capital (Normalized) | −4.33% |
Return on Assets
LAB
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Rknyjvlsd | Hyfrg | $159B | |||
| Stryker Corp
SYK
| Vffmqsph | Btxgf | $120B | |||
| Medtronic PLC
MDT
| Ylgfrmxy | Kxymh | $103B | |||
| Boston Scientific Corp
BSX
| Mkczcmc | Txnkq | $72B | |||
| Edwards Lifesciences Corp
EW
| Jbpfplxym | Gnnbmm | $50B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| Rrwgkyzd | Npnr | $29B | |||
| DexCom Inc
DXCM
| Mdjctwsd | Cffgyzc | $29B | |||
| Koninklijke Philips NV ADR
PHG
| Zdh | Fskd | $26B | |||
| Steris PLC
STE
| Tzpswsw | Bbrsl | $20B | |||
| Zimmer Biomet Holdings Inc
ZBH
| Hgtnwcpvt | Ffzqy | $17B |
United States